Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.18 USD | -0.63% | +1.01% | -35.49% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.49% | 911M | |
+29.29% | 49.46B | |
+0.58% | 42.58B | |
+48.77% | 42.49B | |
-5.26% | 29.09B | |
+12.30% | 26.61B | |
-24.27% | 18.64B | |
+6.87% | 13.16B | |
+31.96% | 12.55B | |
+23.99% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating